You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis

  • Technology appraisal guidance
  • Reference number: TA320
  • Published:  27 August 2014
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • NICE recommends further research to better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a more comprehensive synthesis of available evidence on the underlying disease progression of multiple sclerosis in the UK context, the impact of disability and relapses on preference-based measures of quality of life, and associated resource use and costs.

Back to top